Dark

Check out our Level2View

MDNA
Medicenna Therapeutics Corp. Common Shares
stock NASDAQ

Inactive

Nov 1, 2023

0.1570USD-13.164%(-0.0238)1,267,220

Pre-market

0.00USD-100.000%(-0.18)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

07:00AM EST Medicenna Announces Formation of its Scientific Advisory Board GlobeNewswire Inc

Jan 26, 2022

07:17AM EST Medicenna Highlights Peer-Reviewed Publication Of Preclinical Data On MDNA11 In Journal For ImmunoTherapy Of Cancer Benzinga

07:00AM EST -- MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 GlobeNewswire Inc

Jan 17, 2022

06:00PM EST Medicenna Announces Management Change and Appoints Experienced GlobeNewswire Inc

Jan 5, 2022

07:00AM EST Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that company managementwill be participating in the following virtual investor conferences taking place in January 2022. GlobeNewswire Inc

Dec 22, 2021

08:15AM EST -- Peak CD8+ T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trials first two dose escalation cohorts GlobeNewswire Inc

Dec 17, 2021

07:03AM EST Medicenna Therapeutics Reports Regulatory Clearance To Expand Phase 1/2 ABILITY Study Of MDNA11 To Canada Benzinga

07:00AM EST -- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States GlobeNewswire Inc

Nov 18, 2021

07:00AM EST Medicenna Receives Award for Excellence in Clinical Trials in GlobeNewswire Inc

Nov 16, 2021

10:05AM EST Watching Medicenna Therapeutics; Zacks Small-Cap Research Sets $12 Price Target Benzinga

Nov 12, 2021

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

07:21AM EST Medicenna Therapeutics Q2 EPS $(0.12) Benzinga

07:00AM EST -- Phase 1/2 ABILITY Study of MDNA11 on track for preliminary data updates in calendar 2021 and mid-calendar 2022 GlobeNewswire Inc

04:26AM EST Earnings Scheduled For November 12, 2021 Benzinga

Nov 9, 2021

07:00AM EST Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,will be presenting a corporate overview at Stifels Virtual Healthcare Conference on Monday, November 15, 2021. GlobeNewswire Inc

Nov 4, 2021

08:00AM EDT Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 12, 2021 at 8:30 AM ET to report its second quarter 2022 financial results and operational highlights. GlobeNewswire Inc

Oct 27, 2021

08:57AM EDT Medicenna Announces FDA Clearance Of IND To Expand Phase 1/2 ABILITY Study Of MDNA11 To The United States RTTNews

08:10AM EDT Medicenna Therapeutics Reports FDA Clearance Of Investigational New Drug Application To Expand Phase 1/2 ABILITY Study Of MDNA11 To US Benzinga

08:00AM EDT -- ABILITY Study is currently ongoing at clinical trial sites in Australia GlobeNewswire Inc

Oct 7, 2021

09:05AM EDT -- MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP) GlobeNewswire Inc

Sep 23, 2021

04:30PM EDT Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of John H. Sampson, MD, PhD, MBA, to its Board of Directors and the voting results from the Companys annual meeting of shareholders held today, September23, 2021 (the "Meeting"). GlobeNewswire Inc

Sep 22, 2021

08:00AM EDT Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that members of its leadership team will participate in the Next-Gen Cytokine Therapeutics Summit today. GlobeNewswire Inc

Sep 20, 2021

08:03AM EDT Medicenna Announces Issuance Of U.S. Patent Providing Added Intellectual Property Protection For Its MDNA11 Program Benzinga

08:00AM EDT Medicenna Announces Issuance of U.S. Patent Providing Added GlobeNewswire Inc

Sep 14, 2021

08:02AM EDT Medicenna Doses First Patient In MDNA11 Phase 1/2 ABILITY Study Benzinga

08:00AM EDT -- Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors GlobeNewswire Inc

Sep 9, 2021

09:00AM EDT Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,will be presenting at the following virtual investor conferences to take place in September, 2021. GlobeNewswire Inc

Aug 18, 2021

12:22PM EDT MDNA: On Track to Dose First Patient in MDNA11 Phase 1 Trial in Benzinga

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

07:20AM EDT Medicenna Therapeutics Q1 EPS $(0.12) Misses $(0.08) Estimate Benzinga

07:00AM EDT -- Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021 GlobeNewswire Inc

04:12AM EDT Earnings Scheduled For August 13, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

09:00AM EDT Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 13, 2021 at 8:30 AM ET to report its first quarter fiscal 2022 financial results and operational highlights. GlobeNewswire Inc

Jul 27, 2021

11:13AM EDT Medicenna Therapeutics Reports Initiation Of MDNA11 Phase 1/2 Study Is On Track Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 22, 2021

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

09:06AM EDT Medicenna Therapeutics Corp Highlights Publication Of Preclinical Data On MDNA109 In Frontiers in Immunology Benzinga

09:02AM EDT -- Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression, improved survival, and long-term immune memory effect GlobeNewswire Inc

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 28, 2021

10:31AM EDT MDNA: CTA Submitted in Australia; Phase 1 Trial of MDNA11 to Initiate 3Q21 Benzinga

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

Jun 24, 2021

11:10AM EDT Stocks That Hit 52-Week Lows On Thursday Benzinga

Jun 23, 2021

09:03AM EDT Medicenna Announces Submission Of Clinical Trial Application In Australia For Phase 1/2 Study Of MDNA11 Benzinga

09:00AM EDT -- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021 GlobeNewswire Inc

Jun 7, 2021

06:31AM EDT MDNA: Phase 1 Trial of MDNA11 to Initiate in 3Q21 Benzinga

Jun 1, 2021

06:43AM EDT HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $7 Benzinga

May 28, 2021

07:44AM EDT Medicenna FY Net Loss $17.3 Mln Or $0.35/Shr Vs Loss Of $8.2 Mln Or $0.26/Shr Last Year RTTNews

07:34AM EDT Medicenna FY21 EPS C$(0.35), Down From $(0.26) YoY Benzinga

07:30AM EDT Medicenna Reports Fiscal Year 2021 Financial Results and GlobeNewswire Inc

04:03AM EDT Earnings Scheduled For May 28, 2021 Benzinga

May 20, 2021

09:00AM EDT Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on May 28, 2021 at 8:30 AM ET to report its financial results for the fiscal year ended March 31, 2021 and operational highlights. GlobeNewswire Inc

May 12, 2021

09:01AM EDT Medicenna Names Dr. Mann Muhsin Chief Medical Officer Benzinga

09:00AM EDT Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Mann Muhsin, MD, as the Companys Chief Medical Officer. GlobeNewswire Inc

May 7, 2021

12:02PM EDT Medicenna's MDNA55 Data From Mid-Stage Brain Cancer Study Published In Peer-Reviewed Clinical Cancer Research Benzinga

09:01AM EDT Medicenna Announces Peer-Reviewed Publication Of Clinical Data From Phase 2b Trial Evaluating MDNA55 In Recurrent Glioblastoma Benzinga

09:00AM EDT -- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma GlobeNewswire Inc

Apr 21, 2021

01:51PM EDT MDNA: Targeting 'Cold' Tumors with Dual Cytokine Benzinga

09:03AM EDT Medicenna Therapeutics Names Kevin Moulde As Chief Scientific Officer Benzinga

09:00AM EDT Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Kevin Moulder, PhD, as the Companys Chief Scientific Officer (CSO). GlobeNewswire Inc

Apr 14, 2021

09:00AM EDT Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference onTuesday, April 20th, 2021, at10:00 AM ET. GlobeNewswire Inc

Apr 12, 2021

07:00AM EDT -- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages GlobeNewswire Inc

Mar 25, 2021

07:01AM EDT Medicenna To Present Preclinical Data On MDNA11 With Anti-PD-1 Therapy And Unveil Novel Bifunctional Superkines At Cytokine-Based Cancer Immunotherapies Summit Benzinga

07:00AM EDT -- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model GlobeNewswire Inc

Mar 11, 2021

07:00AM EST Medicenna Therapeutics Announces Upcoming Presentation at the AACR GlobeNewswire Inc

Mar 4, 2021

07:00AM EST Medicenna Therapeutics to Present at Upcoming March Investor GlobeNewswire Inc

Feb 22, 2021

07:00AM EST Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,will present a corporate overview at the 41ST Annual Cowen Healthcare Conference onTuesday, March 2, 2021, at2:10 PM ET. GlobeNewswire Inc

Feb 17, 2021

11:01AM EST Medicenna Therapeutics Shares See Volume; Hearing Zacks Raises Price Target To $12 Benzinga

07:00AM EST Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,will present a corporate overview at the 10thAnnual Leerink Global Healthcare Conference onFriday, February 26th, 2021, at3:00 PM ET. GlobeNewswire Inc

Feb 12, 2021

07:03AM EST Medicenna Q3 EPS $(0.11) vs $(0.07) In same Qtr. Last Year Benzinga

07:00AM EST Medicenna Therapeutics Corp. ("Medicenna" or Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. GlobeNewswire Inc

Dec 30, 2020

06:10PM EST Medicenna Establishes At-the-Market Sales Facility GlobeNewswire Inc

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 18, 2020

10:10AM EST Benzinga's Top Upgrades, Downgrades For December 18, 2020 Benzinga

07:30AM EST Oppenheimer Initiates Coverage On Medicenna Therapeutics with Outperform Rating, Announces Price Target of $12 Benzinga

Dec 17, 2020

04:17PM EST Medicenna Therapeutics Shares Spike Higher, Up 21%; Oppenheimer Initiates Coverage With Outperform, Sets $12 Price Target Benzinga

Dec 9, 2020

07:01AM EST Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit Benzinga

07:00AM EST Medicenna Announces Oral Presentation at the 2nd Annual GlobeNewswire Inc

Dec 2, 2020

07:00AM EST Medicenna Hosting Key Opinion Leader Call on MDNA55 for the GlobeNewswire Inc

Nov 23, 2020

07:30AM EST Medicenna to Participate in Upcoming December Investor Conferences GlobeNewswire Inc

Nov 18, 2020

07:00AM EST Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two on-demand oral presentations as part of the 2020 Society for Neuro-Oncology (SNO) Annual Meeting, which is being held virtually from November 19-21, 2020. GlobeNewswire Inc

Nov 13, 2020

07:16AM EST Medicenna Q2 Net Loss C$3.8 Mln Or C$0.08/Shr Vs Loss C$1.9 Mln Or C$0.07/Shr Last Year RTTNews

07:11AM EST Mediceena Q2 EPS $(0.08) vs $(0.07) In Same Qtr. Last Year Benzinga

07:00AM EST Medicenna Therapeutics Corp. ("Medicenna" or the Company") (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. GlobeNewswire Inc

Nov 2, 2020

07:30AM EST Medicenna to Present at Upcoming Scientific and Investor Events in GlobeNewswire Inc

Oct 26, 2020

08:01AM EDT -- Monotherapy and combination studies continue to demonstrate best-in-class potential of MDNA11 GlobeNewswire Inc

07:08AM EDT Medicenna Highlights Presentation Of Late Breaking Abstract Updating Results From Phase 2b Recurrent GBM Trial At 36th EORTC-NCI-AACR Meeting Benzinga

07:00AM EDT -- Amongst an all-comer population, asingle treatment with MDNA55 resulted inat least 100%increase in both 12 month progression free survival (PFS-12 of 27% versus 2 to 10%) and 2-year survival (OS-24 of 20% vs 5 to10%) when compared to what is achieved with approved therapies GlobeNewswire Inc

Oct 19, 2020

07:00AM EDT Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two abstracts at the EORTC-NCI-AACR ("ENA") Virtual Scientific Program on Molecular Targets and Cancer Therapeutics to be held from October 24 - 25, 2020. GlobeNewswire Inc

Oct 15, 2020

05:30PM EDT - After consultation with the FDA, the company can conduct a hybrid registration trial that allows for the use of matched external controls for two-thirds of control arm - GlobeNewswire Inc

Sep 30, 2020

04:30PM EDT Dr. Jack Geltosky Elected to Medicenna Board of Directors GlobeNewswire Inc

Sep 10, 2020

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 10, 2020 Benzinga

06:15AM EDT HC Wainwright & Co. Initiates Coverage On Medicenna Therapeutics with Buy Rating, Announces Price Target of $8 Benzinga

Sep 9, 2020

07:00AM EDT Medicenna to Present at Upcoming Investor Conferences in September GlobeNewswire Inc

Aug 20, 2020

04:40PM EDT Medicenna to Commence Trading on Nasdaq GlobeNewswire Inc

Aug 4, 2020

07:30AM EDT - Further advances in recurrent glioblastoma program including submission of End of Phase 2 (EOP2) meeting package for MDNA55 GlobeNewswire Inc

Share